LAVAL, Québec and MIGDAL HA’EMEQ, Israel, April 03, 2017 -- Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ:NEPT) (TSX:NEPT) and Enzymotec Ltd., Enzymotec USA, Inc. (together, “Enzymotec”) (NASDAQ:ENZY) are pleased to jointly announce that they have entered into a broad patent cross-licensing agreement, which ends all outstanding litigation between the two companies. The key elements of the settlement and licensing agreement are:
|
|||
- Enzymotec to make a one-time payment of US$1.63 million to Neptune.
- Neptune extends Enzymotec’s worldwide and royalty-free license to its krill-related patents.
- Enzymotec grants Neptune a worldwide and royalty-free license to its krill-related patents.
- The agreement ends all outstanding litigation between the two companies.
“Both parties are satisfied that the integrity of our respective intellectual property was recognized throughout this process and that a final agreement was reached. By ending all legal challenges, we can further concentrate our efforts to the development of the omega-3 krill oil market,” stated Jim Hamilton, President & CEO of Neptune.
Dr. Ariel Katz, President and CEO of Enzymotec commented, “We are pleased that we have come to an amicable solution with Neptune and that we have settled all of our outstanding litigation with them. Furthermore, the agreement promotes our joint efforts to respect the intellectual property of both parties, which is crucial to maintaining the integrity of our respective patent portfolios.”
This long-term agreement should create a lasting patent peace, allowing both companies to focus on growth and business value creation.
About Neptune Technologies & Bioressources Inc.
Neptune is a nutrition products company focused on the business of customized unique nutrition solutions, specialty ingredients and consumer brands. The company develops turnkey solutions available in various unique delivery forms. Neptune also offers premium krill oil manufactured in our state-of-the art facility and a variety of other specialty ingredients such as marine and seed oils. Neptune offers its premium krill oil under the OCEANO3® brand directly to consumers in Canada and the United States through web sales at www.oceano3.com. Oceano3 brand is also sold in bulk to unbranded distributors. The Company’s head office is located in Laval, Québec.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies.
For more information, please contact:
| Neptune Wellness Solutions Mario Paradis VP & CFO, Neptune [email protected] ph: 450-687-2262 x236 Investor Relations Contact (Canada) Pierre Boucher MaisonBrison 1.514.731.0000 [email protected] Investor Relations Contact (U.S.) James Carbonara Hayden IR 1.646.755.4712 [email protected] | Enzymotec Ltd. Oren Bryan Chief Financial Officer Phone: +972747177177 [email protected] Investor Relations Contact (U.S.) The Ruth Group Tram Bui / Lee Roth Phone: 646-536-7035 / 7012 [email protected] [email protected] |


Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable”
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease
AFT Leaves X Over AI-Generated Images of Minors
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 



